Skip to content

Trial Summary

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), themaximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose(RP2D) of repotrectinib given to adult subjects with advanced solid malignant tumors.

Acronym:

TRIDENT-1

ACTRN/NCT /ethics:

NCT03093116

Scientific title:

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Sponsor / Cooperative group:

Turning Point Therapeutics

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2017-02-27
Anticipated End Date-

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Chris Karapetis
Recruitment StatusRecruiting